133 related articles for article (PubMed ID: 1471198)
1. The use of biomarkers in epidemiology: the example of bladder cancer.
Vineis P
Toxicol Lett; 1992 Dec; 64-65 Spec No():463-7. PubMed ID: 1471198
[TBL] [Abstract][Full Text] [Related]
2. Interindividual variation in carcinogen metabolism and bladder cancer risk.
Vineis P; Ronco G
Environ Health Perspect; 1992 Nov; 98():95-9. PubMed ID: 1486869
[TBL] [Abstract][Full Text] [Related]
3. Cytochrome P4501A2: enzyme induction and genetic control in determining 4-aminobiphenyl-hemoglobin adduct levels.
Landi MT; Zocchetti C; Bernucci I; Kadlubar FF; Tannenbaum S; Skipper P; Bartsch H; Malaveille C; Shields P; Caporaso NE; Vineis P
Cancer Epidemiol Biomarkers Prev; 1996 Sep; 5(9):693-8. PubMed ID: 8877060
[TBL] [Abstract][Full Text] [Related]
4. Alkylaniline-hemoglobin adducts and risk of non-smoking-related bladder cancer.
Gan J; Skipper PL; Gago-Dominguez M; Arakawa K; Ross RK; Yu MC; Tannenbaum SR
J Natl Cancer Inst; 2004 Oct; 96(19):1425-31. PubMed ID: 15467031
[TBL] [Abstract][Full Text] [Related]
5. Acetylator phenotype, aminobiphenyl-hemoglobin adduct levels, and bladder cancer risk in white, black, and Asian men in Los Angeles, California.
Yu MC; Skipper PL; Taghizadeh K; Tannenbaum SR; Chan KK; Henderson BE; Ross RK
J Natl Cancer Inst; 1994 May; 86(9):712-6. PubMed ID: 8158701
[TBL] [Abstract][Full Text] [Related]
6. Acetylation phenotype, carcinogen-hemoglobin adducts, and cigarette smoking.
Vineis P; Caporaso N; Tannenbaum SR; Skipper PL; Glogowski J; Bartsch H; Coda M; Talaska G; Kadlubar F
Cancer Res; 1990 May; 50(10):3002-4. PubMed ID: 2334904
[TBL] [Abstract][Full Text] [Related]
7. CYP1A2 and NAT2 phenotyping and 3-aminobiphenyl and 4-aminobiphenyl hemoglobin adduct levels in smokers and non-smokers.
Sarkar M; Stabbert R; Kinser RD; Oey J; Rustemeier K; von Holt K; Schepers G; Walk RA; Roethig HJ
Toxicol Appl Pharmacol; 2006 Jun; 213(3):198-206. PubMed ID: 16405939
[TBL] [Abstract][Full Text] [Related]
8. Molecular epidemiology of bladder cancer.
Vineis P; Martone T
Ann Ist Super Sanita; 1996; 32(1):21-7. PubMed ID: 8967722
[TBL] [Abstract][Full Text] [Related]
9. N-acetyltransferase 2 phenotype but not NAT1*10 genotype affects aminobiphenyl-hemoglobin adduct levels.
Probst-Hensch NM; Bell DA; Watson MA; Skipper PL; Tannenbaum SR; Chan KK; Ross RK; Yu MC
Cancer Epidemiol Biomarkers Prev; 2000 Jun; 9(6):619-23. PubMed ID: 10868698
[TBL] [Abstract][Full Text] [Related]
10. Measurement of 4-aminobiphenyl-hemoglobin adducts in lung cancer cases and controls.
Weston A; Caporaso NE; Taghizadeh K; Hoover RN; Tannenbaum SR; Skipper PL; Resau JH; Trump BF; Harris CC
Cancer Res; 1991 Oct; 51(19):5219-23. PubMed ID: 1913645
[TBL] [Abstract][Full Text] [Related]
11. 4-Aminobiphenyl hemoglobin adducts in fetuses exposed to the tobacco smoke carcinogen in utero.
Coghlin J; Gann PH; Hammond SK; Skipper PL; Taghizadeh K; Paul M; Tannenbaum SR
J Natl Cancer Inst; 1991 Feb; 83(4):274-80. PubMed ID: 1994056
[TBL] [Abstract][Full Text] [Related]
12. Nonsmoking-related arylamine exposure and bladder cancer risk.
Skipper PL; Tannenbaum SR; Ross RK; Yu MC
Cancer Epidemiol Biomarkers Prev; 2003 Jun; 12(6):503-7. PubMed ID: 12814994
[TBL] [Abstract][Full Text] [Related]
13. Polymorphic expression of acetyl coenzyme A-dependent arylamine N-acetyltransferase and acetyl coenzyme A-dependent O-acetyltransferase-mediated activation of N-hydroxyarylamines by human bladder cytosol.
Kirlin WG; Trinidad A; Yerokun T; Ogolla F; Ferguson RJ; Andrews AF; Brady PK; Hein DW
Cancer Res; 1989 May; 49(9):2448-54. PubMed ID: 2784998
[TBL] [Abstract][Full Text] [Related]
14. Haemoglobin adducts formed by aromatic amines in smokers: sources of inter-individual variability.
Ronco G; Vineis P; Bryant MS; Skipper PL; Tannenbaum SR
Br J Cancer; 1990 Apr; 61(4):534-7. PubMed ID: 2331440
[TBL] [Abstract][Full Text] [Related]
15. 4-Aminobiphenyl-DNA adducts and p53 mutations in bladder cancer.
Martone T; Airoldi L; Magagnotti C; Coda R; Randone D; Malaveille C; Avanzi G; Merletti F; Hautefeuille A; Vineis P
Int J Cancer; 1998 Feb; 75(4):512-6. PubMed ID: 9466649
[TBL] [Abstract][Full Text] [Related]
16. Epidemiological models of carcinogenesis: the example of bladder cancer.
Vineis P
Cancer Epidemiol Biomarkers Prev; 1992; 1(2):149-53. PubMed ID: 1306098
[TBL] [Abstract][Full Text] [Related]
17. Black (air-cured) and blond (flue-cured) tobacco cancer risk. IV: Molecular dosimetry studies implicate aromatic amines as bladder carcinogens.
Bartsch H; Malaveille C; Friesen M; Kadlubar FF; Vineis P
Eur J Cancer; 1993; 29A(8):1199-207. PubMed ID: 8518034
[TBL] [Abstract][Full Text] [Related]
18. Hemoglobin adducts of aromatic amines: associations with smoking status and type of tobacco.
Bryant MS; Vineis P; Skipper PL; Tannenbaum SR
Proc Natl Acad Sci U S A; 1988 Dec; 85(24):9788-91. PubMed ID: 3200858
[TBL] [Abstract][Full Text] [Related]
19. Detection of carcinogen-DNA adducts in exfoliated urothelial cells of cigarette smokers: association with smoking, hemoglobin adducts, and urinary mutagenicity.
Talaska G; Schamer M; Skipper P; Tannenbaum S; Caporaso N; Unruh L; Kadlubar FF; Bartsch H; Malaveille C; Vineis P
Cancer Epidemiol Biomarkers Prev; 1991; 1(1):61-6. PubMed ID: 1845172
[TBL] [Abstract][Full Text] [Related]
20. Molecular dosimetry of aromatic amines in human populations.
Skipper PL; Tannenbaum SR
Environ Health Perspect; 1994 Oct; 102 Suppl 6(Suppl 6):17-21. PubMed ID: 7889842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]